Nkarta Inc Ordinary Shares NKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NKTX is a good fit for your portfolio.
News
-
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
-
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
-
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
-
Nkarta to Participate in Upcoming Investor Conferences
-
Nkarta Announces Pricing of $240 Million Underwritten Offering
-
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
-
Nkarta to Participate in Upcoming Investor Conferences
-
Nkarta's Stock Climbs 28% After FDA Approves Drug Application
Trading Information
- Previous Close Price
- $7.56
- Day Range
- $7.02–7.56
- 52-Week Range
- $1.28–16.24
- Bid/Ask
- $7.00 / $7.50
- Market Cap
- $504.96 Mil
- Volume/Avg
- 675,945 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company’s operations are based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 150
- Website
- https://www.nkartatx.com
Comparables
Valuation
|
Metric
|
NKTX
|
ACLX
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.29 | 5.69 | 0.85 |
Price/Sales | — | 23.01 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NKTX
|
ACLX
|
VOR
|
|---|---|---|---|
Quick Ratio | 10.64 | 5.94 | 8.81 |
Current Ratio | 10.85 | 6.06 | 9.04 |
Interest Coverage | — | −23.39 | — |
Quick Ratio
NKTX
ACLX
VOR
Profitability
|
Metric
|
NKTX
|
ACLX
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −22.43% | −6.26% | −41.83% |
Return on Equity (Normalized) | −29.94% | −12.08% | −51.69% |
Return on Invested Capital (Normalized) | −26.92% | −13.11% | −47.03% |
Return on Assets
NKTX
ACLX
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lbjvgpplk | Fqlw | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hyzhwtytq | Sjfjrtp | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hwqfbjpdd | Pkscf | $99.6 Bil | |
MRNA
| Moderna Inc | Gsxjfdgx | Rxyzb | $38.8 Bil | |
ARGX
| argenx SE ADR | Ztpfrzzm | Jhqs | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Pldvmwrq | Kdszc | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykkxspkz | Wzjrcf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hpwzqhds | Hltndk | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Sfkxhnpfm | Qjnkbct | $12.4 Bil | |
INCY
| Incyte Corp | Stvtsxlc | Gxycbft | $11.9 Bil |